Abiopharma

🔍 VanHimbergen Robert M (Executive)

Company: Elanco Animal Health Inc (ELAN)

Report Date: 2026-08-07

Detailed Transactions and Holdings:

• Acquired 4,200 shares of Common Stock at $23.0776 per share (Direct)
  Date: 2026-08-07 | Code: P | equity_swap_involved: 0 | shares_owned_after: 137,516.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 9 shares of Deferred Stock Units (Derivative)
  Date: 2026-08-07 | Code: A | equity_swap_involved: 0 | shares_owned_after: 133.60 | transaction_form_type: 4 | Footnotes: F2, F3, F3

Footnotes:

• F1: Reflects the weighted average price of 4,200 shares of common stock of Elanco Animal Health Inc. purchased by the reporting person in multiple transactions on August 7, 2026 with purchase prices ranging from $23.01 to $23.09 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
• F2: Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent.
• F3: Deferred stock units settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.